Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Zhengye Biotechnology Holding Limited (ZYBT)
USD0.73
+0.02 (+3.04%)
CN NASDAQ Healthcare Drug Manufacturers - Specialty & Generic
Address
No.1 Lianmeng Road 132101
Jilin, CN
Jilin, CN
CEO
Songlin Song
Website
jlzybio.com
IPO
2025-01-07
CIK 1975641 ISIN KYG989MS1016
Description
Zhengye Biotechnology Holding Limited specializes in the creation, manufacturing, and commercialization of animal health immunizations. The company primarily supplies the Chinese agricultural sector with vaccines tailored for a broad spectrum of farm animals, including swine, bovines, goats, ovines, and poultry. Additionally, its product range encompasses inoculations for canines. Beyond its domestic reach, the firm also distributes its offerings to international markets, notably exporting to Vietnam, Pakistan, and Egypt. Established in 2004, this enterprise bases its principal operations in Jilin, China, and operates as a subsidiary entity of Securingium Holding Limited.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.73
+0.02 (+3.04%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
90.2K
Beta
-2.17
Float Shares
4.43M
Free Float %
9.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.23% | -1.94% | -15.54% | +5.63% | -59.46% | -34.78% | -91.94% | -84.57% | -84.57% | -84.57% | -84.57% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.73
DCF (Unlevered)
1.07
+46.3%
DCF (Levered)
0.49
-33.7%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Quality scores
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
4 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-37.6%
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-100.0%
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-21.3%
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-58.8%
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-20.8%
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-100.0% ★
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-1.77×
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-06-12 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-06-11 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-06-10 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-06-09 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-06-08 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-06-05 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-06-04 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-06-03 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-06-02 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-06-01 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-28 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-26 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-19 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-18 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-15 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-12 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
8
Total invested
113.0K
Insider transactions (90d)
0
Beneficial owners (>5%)
1
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Securingium Holding Limited | 42.96M | 90.66% | 42.96M | 42.96M | 42.96M | — | FI | VIRGIN ISLANDS, BRITISH | 2025-02-21 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
8
-2 vs prev Q
New positions
1
Closed positions
3
Increased
2
Reduced
4
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | XTX TOPCO LTD | 44.1K -15.1K (-25.5%) | 41.3K -26.9K (-39.5%) | 0.09% -0.032 pp | 0.00% -0.001 pp | USD2.01 -53.7% | 3 qtrs — |
| 2 | WINTON GROUP LTD | 33.4K -29.9K (-47.3%) | 31.2K -41.6K (-57.1%) | 0.07% -0.063 pp | 0.00% -0.001 pp | USD1.65 -43.6% | 3 qtrs — |
| 3 | GEODE CAPITAL MANAGEMENT, LLC | 29.1K +— (+0.0%) | 27.2K -6.3K (-18.7%) | 0.06% +0.000 pp | 0.00% +0.000 pp | USD5.97 -84.4% | 4 qtrs — |
| 4 | UBS GROUP AG | 8.0K -1.1K (-11.8%) | 7.5K -3.0K (-28.3%) | 0.02% -0.002 pp | 0.00% +0.000 pp | USD3.44 -73.0% | 5 qtrs — |
| 5 | TOWER RESEARCH CAPITAL LLC (TRC) | 4.9K +2.7K (+122.6%) | 4.6K +2.1K (+80.9%) | 0.01% +0.006 pp | 0.00% +0.000 pp | USD2.82 -67.0% | 5 qtrs — |
| 6 | ROYAL BANK OF CANADA | 1.2K +1.2K (+100.0%) | 1.0K +1.0K (+100.0%) | 0.00% +0.003 pp | 0.00% +0.000 pp | USD0.93 +0.0% | 1 qtrs NEW |
| 7 | MORGAN STANLEY | 261.00 -1.3K (-83.8%) | 244.00 -1.6K (-86.8%) | 0.00% -0.003 pp | 0.00% +0.000 pp | USD5.95 -84.4% | 5 qtrs — |
| 8 | CAITONG INTERNATIONAL ASSET MANAGEMENT CO., LTD | 1.00 +— (+0.0%) | 1.00 +— (+0.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.00 -53.5% | 3 qtrs — |
| 9 | JPMORGAN CHASE & CO | — -457.0 (-100.0%) | — -526.0 (-100.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 10 | INVESCO LTD. | — -34.7K (-100.0%) | — -39.9K (-100.0%) | 0.00% -0.074 pp | 0.00% +0.000 pp | USD— | 4 qtrs SOLD |
| 11 | CITADEL ADVISORS LLC | — -30.6K (-100.0%) | — -35.2K (-100.0%) | 0.00% -0.065 pp | 0.00% +0.000 pp | USD— | 3 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
0
Sells
0
Shares acquired
—
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+0
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-24 | Li Guohan (nmn) | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-03-24 | Hu Qiyi | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-03-18 | Sun Wenhua | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-03-18 | Liu Zhongyao | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-03-18 | Lian Wei | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-03-18 | Han Aiden | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-246.3K
Shares Outstanding
47.39M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Aiden Han | Co-Chief Executive Officer | — | male |
| Ping Wang | Chief Financial Officer | — | male |
| Songlin Song | Co-Chief Executive Officer | — | male |
| Yuhong Cheng | Vice General Manager | — | female |
| Zhongyao Liu | Chief Operating Officer | — | male |
ESG Rating
ESG Score History DRUG MANUFACTURERS - SPECIALTY & GENERIC
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ZYBT
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
